COMPANY PROFILE

Kactus Biosystems

Explore full profile

A biotech company focusing on research and development of targeted protein tools

Waltham, United StatesFounded 2018Biotech & Life Sciences

Valuation $100–250M Last recorded · 2022

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Kactus Biosystems

Kactus Biosystems is a cutting-edge biotech company focused on research and development in the fields of immunotherapy, cell and gene therapy, and mRNA treatments. The company operates in the global innovation drug research and development market, providing key protein enzymes for structural design. Kactus Biosystems serves clients that are primarily global innovation drug research and development enterprises, addressing common issues in the protein market such as low success rates and long development periods. The company has developed an exclusive functional repromotion protein and high-activity protein-based R&D platform to overcome these challenges. Kactus Biosystems generates revenue by offering high-quality protein expression services and selling recombinant protein products that maintain high activity levels in cell function assays. The company has successfully completed multiple rounds of financing, including a $30 million Pre-A round and a 40 million yuan A round, demonstrating strong investor confidence.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2018
Headquarters: Waltham, United States
Employees: 32
Open positions: None listed
Dealroom signal: 53.3/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, proteomics, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn X

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

1 recorded event

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES B✓Equity / VC	Oct 2022	$28M	$110M	New Alliance Capital · GF Capital Management & Advisors · Lingang Group	↗

Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

Kactus Biosystems website traffic

Latest recorded traffic for Kactus Biosystems is 620 monthly website visits, up 244.4% over the last three months. Kactus Biosystems's team grew 10.3% over the past year.

Latest monthly visits620 3-month web change+244.4% 1-year team growth+10.3%

Monthly website visitsDec 2022–Mar 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
BRBryleosAdvancing treatment of chronic diseases through early-stage proteomic and metabolomic data analysis	Johnson City, United States	Operational	9	$5.1M	$25M
ETEngimmune TherapeuticsPlatform and product development company engineering next-generation T cell receptor therapies	Allschwil, Switzerland	Operational
BTBAKX TherapeuticsWe create targeted cancer therapies through unique insights into the conformationally dynamic protein drivers of the mitochondrial apoptosis pathway combined with structure-based drug design and computational simulations	Kingston, United States	Closed
DIDIADEMImproves clinicians/patient understanding about risk of Dementia/Alzheimer’s to enable earlier decisions and outcome	London, United Kingdom	Operational
TBTentarix BiotherapeuticsCreates innovative protein therapeutics with uniquely combined bioactivities that leverage powerful synergistic biology	San Diego, United States	Operational
PTPROSION TherapeuticsPROSION Therapeutics is a drug development company with a proprietary platform that addresses highly unmet medical needs by unlocking undruggables	Cologne, Germany	Operational
LELeadartisA company developing bispecific tumor targeted antibodies based on its highly innovative protein engineering platform Trimerbody®	Tres Cantos, Spain	Operational
PRPRAMOMOLECULARDeveloping innovative self-delivering siRNAs to silence the formation of disease-causing proteins to improve the treatment of lung and pancreatic cancer	Berlin, Germany	Operational